Supernus Pharmaceuticals Reports $192.1M Revenue in Q3 2025, Net Loss of $45.1M

Supernus Pharmaceuticals, Inc. reported a total revenue of $192.1 million for the third quarter of 2025, marking a 9% increase from $175.7 million in the same period of 2024. The company's net product sales slightly decreased to $168.5 million from $170.3 million year-over-year, primarily due to declines in sales of APOKYN, Oxtellar XR, and Trokendi XR, which were partially offset by increases in sales of Qelbree and GOCOVRI. The company also recognized $20.2 million in collaboration revenue from ZURZUVAE, reflecting its recent acquisition of Sage Therapeutics, which closed on July 31, 2025. For the nine months ended September 30, 2025, total revenues reached $507.4 million, a 4% increase from $487.7 million in the prior year.

The company's financial performance was impacted by significant increases in selling, general, and administrative expenses, which rose to $179.7 million in the third quarter of 2025 from $69.8 million in the same quarter of 2024. This increase was largely attributed to acquisition-related costs associated with the Sage acquisition, which included transaction costs and accelerated share-based compensation expenses. As a result, Supernus reported a net loss of $45.1 million for the third quarter of 2025, compared to a net income of $38.5 million in the prior year.

In terms of operational developments, Supernus has expanded its product portfolio with the launch of ONAPGO, the first subcutaneous apomorphine infusion device for treating motor fluctuations in Parkinson's disease, which generated $6.8 million in sales during its first full quarter. The company also reported a significant increase in prescriptions for Qelbree, which saw a 31% rise in sales to $81.4 million compared to the previous year. However, the company faced supply constraints for ONAPGO due to higher-than-expected demand, which has affected its ability to meet new patient needs.

The acquisition of Sage Therapeutics has positioned Supernus to enhance its market presence in the central nervous system (CNS) therapeutic area, particularly with ZURZUVAE, which is the first FDA-approved oral treatment for postpartum depression. The acquisition included a contingent consideration liability of $11.4 million, reflecting potential future payments based on sales milestones. The company anticipates that the integration of Sage will contribute positively to its revenue streams, particularly as ZURZUVAE gains traction in the market.

Looking ahead, Supernus expects continued revenue growth driven by its expanding product portfolio and the successful integration of Sage Therapeutics. However, the company also acknowledges potential challenges, including market pressures and the impact of generic competition on existing products. The management remains focused on optimizing operational efficiencies and leveraging its strengthened pipeline to navigate these challenges effectively.